



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

## **Lupin launches generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg**

**Mumbai, Baltimore, August 27, 2018:** Pharma major Lupin announced the launch of Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg (EQ Beyaz®), having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, are the generic equivalent of Bayer's Beyaz® Tablets. It is indicated for use by women to:

- prevent pregnancy;
- treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to use an oral contraceptive for contraception;
- treat moderate acne for women at least 14 years old, only if the patient desires an oral contraceptive for birth control; and
- raise folate levels in women who choose to use an oral contraceptive for contraception.

Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of approximately USD 80.8 million in the US (IQVIA MAT June 2018).

### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8<sup>th</sup> largest generics pharmaceutical company both in terms of market capitalization (30<sup>th</sup> June 2018, Bloomberg) and revenues (31<sup>st</sup> March 2018, Bloomberg LTM) globally. The Company is the 4<sup>th</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (31<sup>st</sup> March 2018, Bloomberg LTM); 6<sup>th</sup> largest generic pharmaceutical player in Japan and 5<sup>th</sup> largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31<sup>st</sup> March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – [www.twitter.com/lupinglobal](http://www.twitter.com/lupinglobal)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

**For further information or queries please contact –**

Pooja Thakran

VP – Corporate Communications

Email: [poojathakran@lupin.com](mailto:poojathakran@lupin.com)

Ph: +91-22-66402531 / 8291013225

Arvind Bothra

Head – Investor Relations

Email:

[arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

Ph: +91-22-66402137

***\*Safe Harbor Statement***

*Beyaz® is a registered trademark of Bayer Aktiengesellschaft.*